May 7, 2021 at 6:40AM Long before they won the 2020 Nobel Prize in Chemistry for discovering the molecular gene-editing tool known as clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, Jennifer Doudna and Emmanuelle Charpentier dreamed of Victoria Gray, a woman with sickle cell disease. Although they didn't know her, they knew that one day, a patient with a genetic disease would be cured using their discovery. Sickle cell disease was the logical place to start since it's the most common blood disorder with a single-gene mutation. CRISPR Therapeutics (NASDAQ:CRSP) is one of several companies using gene editing to fight the illness. Their drug CTX001, developed with partner